Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506776 | 0.89 | CPB2 (0.52) | CPB2ACEPOLBNAMPTCPA1 | |
| SCHEMBL6474709 | 0.83 | CPB2 (0.52) | CPB2ACE | |
| SCHEMBL4502124 | 0.81 | CPB2 (0.48) | CPB2ACEALDH1A1CYSLTR1NAMPT | |
| SCHEMBL4009042 | 0.80 | CPB2 (0.64) | CPB2ACECPA1CPB1 | |
| SCHEMBL4508225 | 0.80 | CPB2 (0.56) | CPB2ACECPA1CPB1 | |
| SCHEMBL4515230 | 0.79 | CPB2 (0.57) | CPB2ACECPB1 | |
| SCHEMBL4521167 | 0.79 | CPB2 (0.57) | CPB2ACECPA1CPB1 | |
| SCHEMBL4509144 | 0.78 | CPB2 (0.46) | CPB2ACEALDH1A1NAMPTCPA1 | |
| SCHEMBL4512112 | 0.78 | CPB2 (0.56) | CPB2ACECPA1CPB1 | |
| SCHEMBL4512159 | 0.77 | CPB2 (0.60) | CPB2ACECPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | METAP1, MPST, DNPEP | CPB2 26/4885ACE 38/4885ALDH1A1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.